Business Wire

XPENG-MOTORS

9.6.2020 19:04:05 CEST | Business Wire | Press release

Share
Xpeng Opens Up New Smart EV Factory

Xpeng Motors, a leading electric vehicle and technology company, today reveals an exclusive inside view into its self-built wholly-owned factory in Zhaoqing, Guangdong Province.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200609005686/en/

The Zhaoqing Xpeng Motors Intelligent Industrial Park, birthplace of the super-long range sports sedan Xpeng P7, was built over a period of 15 months. On May 19, 2020 the factory received the official production license from China’s Ministry of Industry and Information Technology.

Find the pictures and videos revealing the interior of the factory here: https://drive.google.com/drive/folders/1RzxP_eVWDWwVdnfaYTt01G7hn3F-ZZeS?usp=sharing

“We are deeply proud of our achievement as a young company, in building our own wholly-owned smart manufacture base at Zhaoqing,” said He Xiaopeng, Chairman and CEO of Xpeng Motors.

“Xpeng is now the only new smart EV maker in China that has both self-owned and contracted plants. We are a firm believer that manufacturing is the foundation of smart cars. Only when you build solid powertrain and vehicle hardware, can you differentiate with data operation, autonomous driving and connectivity software,” He added.

“This not only gives us optimal insight into and control over our production process, it also demonstrates our capabilities in successfully managing our supply chain and executing major projects. This is a great base for future development in intelligent vehicle design and manufacture,” He concluded.

Spanning a planned area of 3,000 acres (2 million square metres), it has five cutting-edge workshops including stamping, welding, painting, final assembly, and battery pack production.

The factory is run by a 600-member professional team. 74% of the engineers are with 5+ year working experience with 78% joined from leading OEMs.

Stamping Workshop

The stamping workshop is 100% automated. Steel plates are stamped and formed on the 6,600-ton large CNC (computer numerical control) automatic stamping production line, delivering as many as 12 pieces per minute, higher than the 10% industry average, with a precision range as narrow as 0.1 millimeter.

Equipped with an industry-leading information system, the production process is highly open and transparent, with real-time monitoring of processing parameters to ensure high quality consistency.

Welding Workshop

The Zhaoqing welding workshop is equipped with 210 ABB industrial robots, meticulously performing multiple processes including gluing, welding and aluminum plate riveting. Tier-1 and Tier-2 final assemblies reach a 100% automation rate, with the capability to manufacture steel-aluminum hybrid vehicle bodies.

The factory’s self-adaptive medium frequency welding machine achieves 30% energy saving, while the advanced visual gluing system yields gluing accuracy as fine as 0.5 millimeter.

Painting Workshop

Sophisticated styling requires exceptional painting techniques. The Zhaoqing factory’s thin film pretreatment and cathode electrophoretic technology effectively reduces wastewater discharge, while slag yield is also cut down by 94%, reducing energy consumption by approximately 25%, and achieving zero emission of heavy metal pollutants.

The painting workshop adopts world-class BASF high-throwing-power coating material, with B1B2+2K water-based varnish double-layer painting technology, significantly improving paint quality while protecting the environment too.

Assembly Workshop

Thanks to an automatic material supply and distribution system, AGV technology, automatic gluing robots and assembly technology, all components are efficiently and meticulously assembled in the Zhaoqing factory.

All the key torque joints of CBUs (Complete Built Up) are tested online through a powerful digital production system, ensuring 100% quality control of all key torque joints of the build-up.

Battery Pack Workshop

The pack workshop utilizes an AGV flexible production line, combining high-precision visual systems and robots to execute intelligent operations. The intelligent end-of-line testing system conducts comprehensive testing – including 198 offline tests and 89 battery performance tests - for every battery pack, including insulation, SOC performance and BMS function to ensure that every battery pack meets the industry-leading IP68 sealing protection requirements.

The Xpeng P7 will go through 18 vigorous quality control procedures. Each vehicle will also go through over 1,700 dynamic and static tests, and 18 simulated road condition tests for control, braking, comfort, sealing, and abnormal sound to guarantee its quality.

Zhaoqing Xpeng Motors Intelligent Industrial Park – At a Glance

  • Total planned area: 3,000 acres (2 million square metres)
  • Vehicle production facilities area: 1,500 acres (1 million square metres).
  • Phase 1 construction: 900 acres (600,000 square metres)
  • Foundation-laying: December 2017
  • Construction completion: September 2019
  • MIIT production license: received on 19 May 2020
  • Industry 4.0 standards
  • Five workshops
  • 264 intelligent industrial robots

For more P7 videos and images please visit: https://drive.google.com/open?id=1mjds6n51HszTF5YhDcbaViucSwLjeiio

About XPENG Motors

Xpeng Motors is a leading Chinese electric vehicle company that designs and manufactures automobiles that are seamlessly integrated with the Internet and utilize the latest advances in artificial intelligence. The company's initial backers include its Chairman & CEO, He Xiaopeng, who’s also the co-founder of UCWeb Inc. and a former Alibaba executive. Established in 2014, Xpeng Motors has a senior management team with diverse backgrounds, including Co-founders Henry Xia and He Tao, both former senior executives at Guangzhou Auto with expertise in innovative automotive technology and R&D, and Vice Chairman & President Brian Gu, former Chairman of Asia Pacific Investment Banking at J.P. Morgan. It has received funding from strategic investors Alibaba Group and Xiaomi Corporation, as well as other prominent Chinese and international investors including IDG Capital, Morningside Venture Capital, GGV Capital and Primavera Capital. The company launched its first production model, the G3 SUV, in Dec 2018, and will launch its second production model, the P7 electric sports sedan, in April 2020 with deliveries to Chinese customers in Q2 2020. Xpeng Motors is headquartered in Guangzhou, China with offices in Beijing, Shanghai, Silicon Valley and San Diego in the U.S. and manufacture centers in Zhengzhou and Zhaoqing. For more information, please visit the official website: https://en.xiaopeng.com/

Follow us on social media for latest Xpeng news:

Facebook Twitter LinkedIn YouTube Instagram

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye